Capricor Therapeutics (NASDAQ:CAPR) CFO Sells $15,000.00 in Stock

Capricor Therapeutics, Inc. (NASDAQ:CAPR) CFO Anthony Bergmann sold 500 shares of the stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $30.00, for a total value of $15,000.00. Following the sale, the chief financial officer owned 11,223 shares in the company, valued at approximately $336,690. This represents a 4.27% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Anthony Bergmann also recently made the following trade(s):

• On Wednesday, June 24th, Anthony Bergmann sold 400 shares of Capricor Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $12,000.00.
• On Friday, May 1st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The shares were sold at an average price of $31.70, for a total value of $792,500.00.
• On Tuesday, March 31st, Anthony Bergmann sold 25,000 shares of Capricor Therapeutics stock. The stock was sold at an average price of $30.13, for a total value of $753,250.00.

Capricor Therapeutics Stock Down 13.0%

Shares of NASDAQ CAPR opened at $26.44 on Friday. Capricor Therapeutics, Inc. has a 52 week low of $4.30 and a 52 week high of $40.37. The business has a 50-day simple moving average of $30.00 and a two-hundred day simple moving average of $28.41. The company has a market cap of $1.53 billion, a P/E ratio of -11.40 and a beta of 0.39.

Capricor Therapeutics (NASDAQ:CAPR) last posted its earnings results on Tuesday, May 12th. The biotechnology company reported ($0.59) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.04). Equities research analysts anticipate that Capricor Therapeutics, Inc. will post -0.75 EPS for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. Royal Bank of Canada lifted its stake in Capricor Therapeutics by 12.4% in the fourth quarter. Royal Bank of Canada now owns 5,040 shares of the biotechnology company’s stock worth $146,000 after purchasing an additional 557 shares during the last quarter. KBC Group NV bought a new position in shares of Capricor Therapeutics during the first quarter valued at about $44,000. ACT Capital Management LLC bought a new position in shares of Capricor Therapeutics during the fourth quarter valued at about $43,000. Nuveen LLC increased its holdings in shares of Capricor Therapeutics by 2.1% in the fourth quarter. Nuveen LLC now owns 90,951 shares of the biotechnology company’s stock worth $2,625,000 after buying an additional 1,878 shares during the period. Finally, State of Wyoming increased its holdings in shares of Capricor Therapeutics by 76.0% in the fourth quarter. State of Wyoming now owns 4,429 shares of the biotechnology company’s stock worth $128,000 after buying an additional 1,913 shares during the period. Institutional investors own 21.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CAPR shares. Cantor Fitzgerald set a $62.00 target price on shares of Capricor Therapeutics and gave the stock an “overweight” rating in a research report on Friday, March 13th. B. Riley Financial lifted their price target on Capricor Therapeutics from $50.00 to $63.00 and gave the stock a “buy” rating in a research note on Friday, March 13th. Roth Mkm reiterated a “buy” rating and set a $38.00 price objective on shares of Capricor Therapeutics in a research report on Friday, May 15th. Piper Sandler reiterated an “overweight” rating and set a $58.00 price objective (up from $45.00) on shares of Capricor Therapeutics in a research report on Friday, March 13th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Capricor Therapeutics in a report on Monday, June 15th. Eight research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $50.30.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.